TwoXAR
2014
United States of America based
$14.300 M
http://www.twoxar.com/
The convergence of big data, cloud computing, and artificial intelligence has allowed twoXAR to build a drug discovery platform that is order of magnitudes faster, cheaper, and more accurate than traditional wet-lab based approaches.
twoXAR leverages its technology internally to build its own pipeline of therapeutic candidates across diseases as well as collaborate with biotechnology and pharmaceutical companies to jointly discover and develop novel drug candidates by:
- Screening compound libraries for efficacy against a disease or list of diseases
- Screening compound libraries for efficacy against a disease or list of diseases
- Identifying biologic targets from the elucidation of novel biology
Technologies
AI Companies (Drug Discovery) Pharmaceutical and Drug DiscoveryPosts Mentioning This Company
R&D Platform
Screen compound libraries for efficacy against a disease, identify new drug candidates from a public library, and identify biologic targets. Allows researchers to: Speed and reduce costs for drug discovery.
Pipelines
None
twoXAR Pharmaceuticals has rapidly identified potential new therapies for a wide range of diseases and currently has a pipeline for over 18 different disease programs.
Products
Services
No services posted yet